Context Therapeutics Inc (CNTX) — Titan Protect Analysis

CNTX

Context Therapeutics Inc

Healthcare · ·

$1.75

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$211M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-5.32

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-56.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$6.00

+243% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 7 analysts covering this stock

About Context Therapeutics Inc

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated

https://www.contexttherapeutics.com

Country: United States Employees: 15 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.505

Good returns relative to risk taken

Kelly Fraction

0.0051

Marginal edge — very small allocation suggested

Calmar Ratio

0.086

Drawdown risk outweighs the returns — higher risk profile

Annual Return

6.8%

Historical annualised return based on price data

Max Drawdown

-79.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.57

Significantly more volatile than the market

52W High

$3.62

52% below the year high

52W Low

$0.52

235% above the year low

Avg Volume

863,665

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.42

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.54

Moderate leverage — manageable

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-23,796,480

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-40,226,928

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$8.00

Target Median

$6.00

Target Low

$4.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go